Results 11 to 20 of about 9,514 (200)

Mitoxantrone—A Hypomethylating Agent? [PDF]

Cancer Biology & Therapy, 2003
Commentary to: Mitoxantrone Mediates Demethylation and Re-Expression of Cyclin D2, Estrogen Receptor 14.3.3 Sigma In Breast Cancer Cells Belinda S. Parker, Suzanne M. Cutts, Abraham Nudelman, Ada Rephaeli, Don R.
Allen S. Yang, Jean-Pierre J. Issa
openaire   +1 more source

Pseudo-differentiation syndrome

Mediterranean Journal of Hematology and Infectious Diseases, 2011
A patient with relapsed acute myeloid leukemia (AML) (M2) FAB classification developed a differentiating syndrome upon receiving Decitabine therapy given with palliative intent.
Dina Khalaf, Fathi Jehani
doaj   +3 more sources

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Acta Medica Bulgarica, 2021
Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Nikolova D., Yordanov A., Radinov A.
doaj   +1 more source

Maintenance Therapy in AML

Frontiers in Oncology, 2021
Recent advances in therapeutics coupled with steady improvements in supportive care for patients with acute myeloid leukemia (AML) have led to improved outcomes.
Patrick K. Reville, Tapan M. Kadia
doaj   +1 more source

TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE

Mediterranean Journal of Hematology and Infectious Diseases, 2016
Objectives: Low-dose cytarabine (LD-AraC) is still regarded as the standard of care in elderly patients with acute myeloid leukemia (AML) ‘unfit’ for intensive chemotherapy.
Maël Heiblig, Mohamed Elhamri, Isabelle Tigaud, Adriana Plesa, Fiorenza Barraco, Hélène Labussière, Sophie Ducastelle, Mauricette Michallet, Franck Nicolini, Claudiu Plesa, Eric Wattel, Gilles Salles, Xavier Thomas   +12 more
doaj   +1 more source

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia

Therapeutic Advances in Hematology, 2021
In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine).
Nerea Báez-Gutiérrez, Héctor Rodríguez-Ramallo, María Antonia-Pérez Moreno, Eduardo-Rodriguez Arboli, Laila Abdel-kader Martín   +4 more
doaj   +1 more source

Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)

Acta Medica Bulgarica, 2020
Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.
Varbanova V., Anastasova-Postadzhiyan A., Nedeva A., Nikolov I., Kindekov I., Kuyumdzhieva Y., Petkova N., Vikentieva E., Lubomir M., Raynov J.   +9 more
doaj   +1 more source

Clinical Results of Hypomethylating Agents in AML Treatment [PDF]

Journal of Clinical Medicine, 2014
Epigenetic changes play an important role in the development of acute myeloid leukemia (AML). Unlike gene mutations, epigenetic changes are potentially reversible, which makes them attractive for therapeutic intervention. Agents that affect epigenetics are the DNA methyltransferase inhibitors, azacitidine and decitabine.
Cruijsen, Marjan, Lübbert, Michael, Wijermans, Pierre W., Huls, Gerwin   +3 more
openaire   +3 more sources

Transplantation for myelodysplastic syndrome in the era of hypomethylating agents [PDF]

Current Opinion in Hematology, 2012
This review summarizes the available data on the role of hypomethylating agents in the setting of hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS).Although hypomethylating agents have been established as standard of therapy for MDS in the nontransplant setting, the role of these agents in patients who are candidates for HCT ...
Aaron T, Gerds, H Joachim, Deeg
openaire   +2 more sources

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia

Haematologica, 2020
In older patients with acute myeloid leukemia, the more frequent presence of biologically inherent therapy-resistant disease and increased comorbidities translate to poor overall survival and therapeutic challenges. Optimal front-line therapies for older
Chetasi Talati, Varun C Dhulipala, Mar tine Extermann, Najla Al Ali, Jongphil Kim, Rami Komrokji, Kendra Sweet, Andrew Kuykendall, Marina Sehovic, Tea Reljic, Benjamin Djulbegovic, Jeffrey E. Lancet   +11 more
doaj   +1 more source